Clin2
NCT07211802Possibly a fitNot yet recruiting

Using SGLT2i safely in type 1 diabetes

Type 1 Diabetes (T1D)

Part of Hormones & metabolism, Immune system & allergy clinical trials.

This study tests if a special monitoring system can help people with type 1 diabetes use SGLT2i medications safely, alongside insulin and a continuous glucose monitor.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
52 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • Must be over 18 years old
  • Diagnosed with type 1 diabetes for at least one year
  • Using a stable insulin plan (pump or injections) for at least 8 weeks
  • Currently using a continuous glucose monitor (CGM)
  • Kidney function (eGFR) must be 60 or higher

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07325201Not yet recruiting· Phase 2
Preventing DKA with continuous ketone monitoring in type 1 diabetes

This study tests a dual continuous ketone and glucose monitor to help prevent diabetic ketoacidosis (DKA) in people with type 1 diabetes who are starting SGLT2 inhibitor treatment. SGLT2 inhibitors are a newer type of diabetes medicine, but they can increase the risk of DKA. The device may make using these medicines safer.

Minneapolis, Minnesota
NCT06753994Recruiting· Phase 1
Continuous ketone monitoring in type 1 diabetes with SGLT2 inhibitors

This study tests a new sensor that continuously measures ketone levels in people with type 1 diabetes who are also taking SGLT2 inhibitors. It aims to see if the sensor can help prevent diabetic ketoacidosis.

Montreal, Quebec
NCT07421518Not yet recruiting· Phase 2
Ketone monitoring to prevent DKA with SGLT2 inhibitors in type 1 diabetes

This study tests a device that monitors ketone levels to help reduce the risk of diabetic ketoacidosis (DKA) for people with type 1 diabetes who are taking a class of medications called SGLT-2 inhibitors. The goal is to see if regular ketone tracking can make these medications safer.

Orlando, Florida
NCT07595289Not yet recruiting
Dapagliflozin with continuous glucose monitoring for type 2 diabetes

This study tests whether a diabetes medication called dapagliflozin works better when paired with continuous glucose monitoring (a sensor that checks blood sugar all day) compared to finger-stick blood tests. The goal is to help you control your blood sugar more effectively.

NCT05960656Recruiting· Phase 1
Study of SGLT2 inhibitor effects on liver sugar production

This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.

San Antonio, Texas
NCT07225465Not yet recruiting· Phase 2
Safe ketone levels with dapagliflozin for type 1 diabetes

This study tests whether a medication called dapagliflozin (a type of SGLT2 inhibitor) can be used safely in people with type 1 diabetes by checking blood ketone levels. It may help find a way to lower the risk of a serious condition called ketoacidosis while using this medication.

Fitzroy, Victoria

Hear when a new Type 1 Diabetes (T1D) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.